Founded in 1986, Shire Pharmaceuticals Group plc is a rapidly growing international emerging pharmaceutical company with revenues for the full year 2002 of $1,037.3 million and an operating income of $327.038 million. The growth rates for revenues were 22% for 2002.
Shire intends to grow both organically and by acquisition. The business development team at Shire focuses on the ‘search’ aspect of the Search and Development strategy.
- pharmaceutical shares
- richard de souza, director international
- alzheimers disease
- essential thrombocythaemia
They are mainly involved in the acquisition of companies and in- and out-licensing
of marketed products and development projects. For more information, click
on the appropriate link above.
We aim to provide high quality and effective products that enhance the health and quality of life of people around the world and contribute to the long-term business success of our company, to the benefit of all our stakeholders.
We are driven
by the needs of all our stakeholders: patients, their families and caregivers,
doctors and medical specialists, employees and partner companies, the
community in which we live and work and of course our shareholders.
medications
We also want to be the employer of choice in our sector, attracting and retaining highly skilled and talented people who play an active part in the development of our company by rewarding excellence and recognising individual contributions - medications
We are guided
by our values: dynamism, integrity, caring and innovation, which govern
our day-to-day actions that will all, ultimately, ensure that we achieve
our mission.
specialty and pharmaceutical companies
mecloderm uk
adderall research
treatment osteoperosis
adept adhesions
shire germany
shire pharmaceuticals
As part of our history
we have acquired and merged with a number of other companies. This has
led to a wide ranging portfolio of products not always within our primary
therapeutic areas of interest. However, these products are useful for
many patients and together continue to provide strong revenues that we
are able to plough back into the development of new products for the future
benefit of many more patients.
Shire Pharmaceuticals Group plc (Shire) is a rapidly growing international
emerging pharmaceutical company with a strategic focus on four therapeutic
areas - central nervous system disorders (CNS), gastrointestinal (GI),
oncology, and anti-infectives. Shire also has three platform technologies:
advanced drug delivery, lead optimisation for small molecules and Biologics.
Shire's core strategy is based on research and development combined with
in-licensing and a focus on key pharmaceutical markets.